Authors
Ronald D. Wiehle, Ph.D., Gregory Fontenot, Ph.D., Jenny Wike, B.S., Kuang Hsu, M.S., Jennifer Nydell, B.S. Larry Lipshultz, M.D.
Volume 102, Issue 3, Pages 720-727
Abstract
Objective:
To determine the effect of enclomiphene citrate in men with secondary hypogonadism.
Design:
Phase II clinical trial.
Setting:
Community dwelling men making visits to physician offices.
Patient(s):
Men with secondary hypogonadism.
Intervention(s):
Oral administration of enclomiphene citrate or 1% topical T gel.
Main Outcome Measure(s):
Luteinizing hormone, FSH, T, and semen analysis.
Result(s):
Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. Follicle-stimulating hormone and LH were increased with enclomiphene, and sperm counts were conserved.
Conclusion(s):
Enclomiphene citrate reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production.
Clinical Trial Registration Number:
NCT01270841 (ClinicalTrials.gov Identifier NCT01270841).
Read the full text at: http://www.fertstert.org/article/S0015-0282(14)00537-8/fulltext